Indicated for improving luminal diameter in patients, including those with bleeding risks or those who have to undergo DAPT interruption in the near future for any surgery and who have associated risks, such as diabetes mellitus, symptomatic coronary artery disease, stable angina, unstable angina, or documented silent ischemia due to atherosclerotic lesions in native coronary arteries with a reference vessel diameter 2.25–4 mm and lesion length of ≤ 36 mm
iVascular
Angiolite BTK
Sirolimus
Cobalt chromium (CoCr L605)
Biostable fluorinated acrylate
0.014
5
2, 2.25, 2.5, 2.75, 3, 3.5, 4, 4.5
9, 14, 16, 19, 24, 29, 34, 39
142
Indicated for treating chronic and acute arterial lesions in the lower limbs below the knee, as well as popliteal and infrapopliteal lesions with reference vessel diameters between 2–4.5 mm, with the aim of increasing the internal diameter of an artery and consequently improving blood flow in the following cases: severe claudication and critical limb ischemia; also indicated for the treatment of erection-related arterial lesions in patients with arteriogenic erectile dysfunction to restore arterial flow to the corpora cavernosa
Indicated for improving infrapopliteal luminal diameter for the treatment of occlusive lesions BTK and above the ankle that lead to severe claudication or CLI; treated infrapopliteal arteries must have a reference diameter ranging between 2.25–4 mm